Rigel Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Rigel Pharmaceuticals's estimated annual revenue is currently $147.3M per year.
- Rigel Pharmaceuticals received $71.8M in venture funding in April 2018.
- Rigel Pharmaceuticals's estimated revenue per employee is $564,291
- Rigel Pharmaceuticals's total funding is $192.5M.
- Rigel Pharmaceuticals's current valuation is $413.8M. (January 2022)
Employee Data
- Rigel Pharmaceuticals has 261 Employees.
- Rigel Pharmaceuticals grew their employee count by -2% last year.
Rigel Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Rigel Pharmaceuticals?
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$192.5M
Total Funding
261
Number of Employees
$147.3M
Revenue (est)
-2%
Employee Growth %
$413.8M
Valuation
N/A
Accelerator
Rigel Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP, Corporate Affairs and General Counsel | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | Account Executive | Reveal Email/Phone |
4 | Associate Director, Regional Marketing | Reveal Email/Phone |
5 | Territory Business Manager | Reveal Email/Phone |
6 | CFO | Reveal Email/Phone |
7 | Associate Director Clinical Operations | Reveal Email/Phone |
8 | Executive Business Development Director | Reveal Email/Phone |
9 | National Sales Director | Reveal Email/Phone |
10 | Territory Business Manager | Reveal Email/Phone |
Rigel Pharmaceuticals News
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 22.3% in March. Posted by admin on Apr 18th, 2022. Share on Twitter Share on Facebook Share on...
Rigel Pharmaceuticals, Inc. (RIGL) stock is down -13.85% over the last 12 months, and the average rating from Wall Street analysts is a...
In early March, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) reported a near miss on revenues for Q4'21, but the stock rallied nonetheless and...
Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA), topline data expected mid-2022 - Rigel's Phase 3 trial in high-risk hospitalized patients ...
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $95.1M | 262 | 5% | N/A |
#2 | $197.9M | 266 | -11% | $194.5M |
#3 | $29.7M | 270 | 7% | N/A |
#4 | $10.1M | 300 | -13% | N/A |
#5 | $69M | 318 | 19% | $743M |
Rigel Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-01-18 | $31.5M | Public Offering | Article | |
| 2003-05-01 | $46.0M | Lead Investor: MPM C | Article | |
| 2003-06-30 | $46.0M | Common Stock | MPM Capital | Article |
| 2003-08-04 | $9.3M | Rights Offering | Article | |
| 2009-09-19 | $108.3M | Undisclosed | Credit Suisse Securities (USA) | Article |
| 2011-05-26 | $Undisclosed | Undisclosed | Jefferies & Company Inc, J P Morgan Securities LLC | Article |
| 2012-10-04 | $130.0M | Undisclosed | Jefferies & Company Inc, J P Morgan Securities LLC | Article |
| 2017-02-01 | $40.0M | Undisclosed | Jefferies LLC | Article |
| 2017-10-04 | $46.0M | Undisclosed | Jefferies LLC | Article |
| 2017-10-05 | $69.7M | Undisclosed | BMO Capital Markets Corp | Article |
| 2018-04-20 | $71.8M | Undisclosed | Jefferies LLC | Article |